

LAW OFFICES

KILYK & BOWERSOX, P.L.L.C.

*Intellectual Property Law*RECEIVED
CENTRAL FAX CENTER

APR 08 2005

LUKE A. KILYK* (PA, DC)
LEONARD D. BOWERSOX
JASBIR SINGH
MATTHEW T. GILL
RALPH T. WEBB* (DC, TX, LA)
SUSANNE M. HOPKINS
J. MARK KONIECZNY* (MA)

53 A East Lee Street
WARRENTON, VA 20186

TEL.: (540) 428-1701
FAC.: (540) 428-1720
(540) 428-1721

FAIRFAX OFFICE
3603-E Chain Bridge Road
Fairfax, Virginia 22030

Email: lkilyk@kbpattentlaw.com
Website: <http://www.kbpattentlaw.com>

Of Counsel:
WILLIAM CHARLES JAMISON

*Admitted only in states indicated

PLEASE DIRECT CORRESPONDENCE TO OUR WARRENTON OFFICE

FACSIMILE TRANSMISSION COVER SHEET

DATE: April 8, 2005

TO: Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RE: U.S. Patent Application No. 10/516,558
Entitled: RB1 GENE INDUCED PROTEIN (RB1CC1) AND GENE
Our Ref.: 3190-070

FROM: Luke A. Kilyk, Esq. *SK*

FAC. TEL. NO.: 1-703-872-9306

NUMBER OF PAGES (INCLUDING THIS COVER SHEET): 12

Items Attached: Supplemental Information Disclosure Statement -- 2 pages
Form PTO 1449 -- 1 page
Document -- 8 pages

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. 1-703-872-9306 on April 8, 2005.

Donald S. Prater
Name (Print)

Donald S. Prater
Signature

THE INFORMATION CONTAINED IN THIS MESSAGE IS CONFIDENTIAL INFORMATION INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY TO WHICH IT IS ADDRESSED. This message may also be an attorney/client communication which is privileged and confidential. If the reader of this message is not the intended recipient, or the employee or agent responsible to deliver it to the intended recipient, you are hereby notified that any distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by calling us collect and return the original message to us at the above address by mail. Thank you.

BEST AVAILABLE COPY

APR 08 2005

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. 1-703-872-9306 on April 8, 2005.

Donald S. Prater
Name (Print)

Donald S. Prater
Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	Chano et al.)	Examiner:	Unassigned
)		
Application No.:	10/516,558)	Group Art Unit:	Unassigned
)		
Filed:	November 30, 2004)	Confirmation No.:	Unassigned
)		
Docket No.:	3190-070)	Customer No.:	33432

For: RB1 GENE INDUCED PROTEIN (RB1CC1) AND GENE

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 CFR 1.97(b)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

April 8, 2005

Sir:

The attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached Form PTO-1449. Pursuant to the current United States Patent and Trademark Office rules, no copies of U.S. Patents/Patent Application Publications are provided.

This Information Disclosure Statement is being submitted after expiration of the three-month period following filing of the above-captioned application, but before an Office Action on the merits and before any Final Office Action or Notice of Allowance.

Should a first Office Action cross in the mail with the filing of this Supplemental Information Disclosure statement, then applicants respectfully petition under 37 C.F.R. § 1.97(c) to consider the documents set forth in the Supplemental Information Disclosure Statement.

The above information is presented so that the Patent and Trademark Office can, in the first instance, determine any materiality thereof to the claimed invention. See 37 CFR 1.104(a) and

BEST AVAILABLE COPY

Supplemental Information Disclosure Statement
U.S. Patent Application No. 10/516,558

1.106(b) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the documents cited in the attached Form PTO-1449 be made of record therein and appear on the first page of any patent to issue therefrom.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in this application and applicant determines that the cited documents do not constitute "prior art" under United States law, applicant reserves the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

It is believed that no fee is required to make this a complete and timely filing. However, if it is determined that a petition or fee is required, the Commissioner is hereby authorized to charge any fee associated with this statement to our Deposit Account No. 50-0925.

Respectfully submitted,



Luke A. Kilyk
Reg. No. 33,251

Atty. Docket No.: 3190-070
KILYK & BOWERSOX, P.L.L.C.
53 A East Lee Street
Warrenton, VA 20186
Tel.: (540) 428-1701
Fax: (540) 428-1720
Enclosures: PTO-1449, w/1 Document

Page 1 of 1

FORM PTO-1449 (REV 7-80)	Atty. Docket No. 3190-070	Application No. 10/516,558
INFORMATION DISCLOSURE STATEMENT	APPLICANT: CHANO et al.	
	Filing Date: November 30, 2004	Group Art Unit: Unassigned

U.S. PATENT DOCUMENTS							
EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE, IF APPROPRIATE

FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	International Preliminary Examination Report for PCT/JP2003/000882 dated February 24, 2005. (English Translation)

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

BEST AVAILABLE COPY